Postoperative Adjuvant Therapy of HCC Based on PD-1
NCT05307926
·
clinicaltrials.gov ↗
COMPLETED
Status
573
Enrollment
OTHER
Sponsor class
Conditions
Hepatocellular Carcinoma
RFS
Interventions
DRUG:
PD-1 inhibitors
PROCEDURE:
TACE
Sponsor
Chen Xiaoping